Logo

Multiple Myeloma

Trial_locations_btn

ACY-1215 Clinical Trials

Acetylon is currently sponsoring multiple clinical trials of ACY-1215. One trial (‘100’ study) is evaluating ACY-1215 when used alone and in combination with Velcade® (bortezomib) and dexamethasone. Another trial (‘101’ study) is evaluating ACY-1215 when used in combination with Revlimid® (lenalidomide) and dexamethasone.

ACY-100 study: A Phase I/II, Open-label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with bortezomib and dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

The ‘100’ study is a three-part study conducted at multiple sites across the US, and is partially funded by the Leukemia & Lymphoma Society. In Phase I (a and b), the maximum tolerated dose of ACY-1215 will be determined, alone and in combination with bortezomib and dexamethason. In Phase II, the efficacy of ACY-1215 will be evaluated in combination with bortezomib and dexamethasone. To find out more about this study please refer to clinicaltrials.gov study NCT 01323751.

Georgia

Winship Cancer Institute, Emory University
Atlanta, GA 30322

Contact:
Cathy Sharp
Phone:
404-778-3811
Email:

Principal (Lead) Investigator:
Sagar Lonial, MD

Massachusetts

Massachusetts General Hospital
Boston, MA 02115

Contact:
Chi La
Phone:
617-724-5251
Email:

Principal Investigator:
Noopur Raje, MD

New York

Mt. Sinai Medical Center
New York, NY 10029

Contact:
Kenneth Lau
Phone:
212-241-7846
Email:

Principal Investigator:
Sundar Jagganath, MD

Pennsylvania

University of Pennsylvania
Philadelphia, PA 19104

Contact:
Kristy Walsh
Phone:
215-615-4822
Email:

Principal Investigator:
Dan Vogl, MD

Texas

MD Anderson Cancer Center
Houston, TX 77030

Contact:
Martha Anderson, RN
Phone:
713-794-1079
Email:

Principal Investigator:
Robert Orlowski, PhD, MD

Wisconsin

Medical College of Wisconsin - Clinical Cancer Center
Milwaukee, WI 53226

Contact:
Paulette Jacobs
Phone:
414-805-4594
Email:

Principal Investigator:
Parameswaran Hari, MD


ACE-MM-101 study: A Phase I, Open-label, Multicenter Study of ACY-1215 in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

The ‘101’ study is being conducted at multiple sites across the US. This study will assess the maximum tolerated dose of ACY-1215 in combination with Revlimid (lenalidomide) and dexamethasone. (more sites to follow)

To find out more about this study and to find out where this study is being conducted, please refer to clinicaltrials.gov study NCT 01583283.

Massachusetts

Massachusetts General Hospital
Boston, MA 02114

Contact
Theresa Le
Email:

Principal Investigator:
Anuj Mahindra, MD

North Carolina

University of North Carolina at Chapel Hill
Chapel Hill, NC 27514

Contact:
Elizabeth Tita
Phone:
919-843-7657
Email:

Principal Investigator:
Peter Voorhees, MD

Tennessee

Sarah Cannon Research Institute
Nashville, TN 37203

Contact:
Cindy Farley
Phone:
615-329-7237
Email:

Principal Investigator:
Jesus Berdeja, MD

Washington

Fred Hutchinson Cancer Research Center
Seattle, WA 98109

Contact:
Cari Morin
Phone:
206-667-6238
Email:

Principal Investigator:
William Bensinger, MD